

Melanoma therapy Options in 2012

	Setting	Therapeutic Options
<p>First line-</p> <p>Genotype for at least BRAF (Cobas™ or Sanger sequencing) and c-kit mutations</p> <p>Also NRAS, GNA11, GNAQ-uveal</p>	<p>BRAF mutated</p>	<p><i>Patient with sx, bulky disease, or Increased LDH</i></p> <p><i>Vemurafenib</i></p>
		<p><i>Indolent disease-asx, M1a /M1b, asx</i></p> <p><i>Vemurafenib or Ipilimumab</i></p> <p><i>HD IL-2 first line (in select patients)</i></p>
		<p><i>Trial options:</i></p> <p><i>BRAF_i+MEK_i</i></p> <p><i>BRAF_i + Ipilimumab</i></p>
	<p>C-kit</p>	<p><i>Clinical trials with nilotinib, sunitinib or imatinib</i></p> <p><i>Alternative Ipilimumab or HD IL-2</i></p>
<p><i>BRAF wt or NRAS</i></p>	<p><i>HD IL-2 (select patients), Ipilimumab</i></p> <p><i>Clinical trials</i></p> <p><i>Chemotherapy (DTIC, TMZ, Taxane)</i></p>	